An urgent need for standardization of stem cells and stem cell‐derived products toward clinical applications
T. Lappin,T. Cheng
DOI: https://doi.org/10.1002/sctm.21-0269
2021-11-01
Stem Cells Translational Medicine
Abstract:Stem cells are defined by their abilities to self-renew and differentiate into various cell lineages with the physiological “SMART” feature, which makes them attractive cell sources for the treatment of a broad range of diseases requiring tissue regeneration, such as hematopoietic/immune diseases, cancers, and many other degenerative disorders. In addition to hematopoietic stem cell (HSC) transplantation, which has been the classic stem cell therapy used mainly for hematopoietic diseases, other tissue stem cells and embryonic stem cells (ESC) or induced pluripotent stem cell (iPSC)-derived cell products also offer unique or alternative regenerative sources for stem cell therapies. However, despite enormous progress in basic stem cell research during the past two decades since the establishment of human ESC lines, and especially the later Nobel-winning iPSC technology, translation of many basic discoveries on stem cells into clinical practice has been disappointingly limited and, problematically, some unproven stem cell therapies still exist. One of the bottleneck factors limiting the pace of translational stem cell medicine is the significant lack of stem cell standardization and guidelines for many stem cell therapies. Back in 2000, the Cellular, Tissue, and Gene Therapies Advisory Committee meeting in Gaithersburg, Maryland, held by the U.S. Food and Drug Administration (FDA), recommended that the regulations for other cellular therapy products could also be applied to stem cell products. In 2009, the FDA revised and established a set of regulations and guidelines to improve the safety of regenerative therapy. Recently, the International Society for Stem Cell Research issued new guidelines for the clinical application of stem cell products. In light of this regulatory guidance, aiming to best serve our patients, specific standard measures for each type of stem cell product are an essential requirement. This issue is even more important and urgent for China, where stem cell science has rapidly risen to the front line and a higher expectation has been set for stem cell products to serve the most populated nation in the world. Therefore, it is necessary and would be valuable to share the views and practical guidelines on this important topic to better meet the need in the field. This Special Edition of STEM CELLS Translational Medicine, inspired by the proceedings of the seventh International Forum on Stem Cells (IFSC) held in Tianjin in November 2020, illustrates the prevailing view that advances in stem cell biology are bringing regenerative medicine a step closer. In particular, this issue contains a number of review articles summarizing the current advances in stem cell translation and the development of reliable standardization for preclinical assessment of stem cell products. In the first of two Perspectives, Haidan Chen describes how the complexities of translating scientific discovery into clinically efficacious stem cell therapy are managed in the Tianjin model of stem cells translational medicine. The author shows how scientific, technological, social, economic, and political variables are coordinated in the efforts to make cell therapy available in China. Dr Chen goes on to compare the perceived strengths and weaknesses of the Tianjin model with translational programs in Europe and the United States. In the second Perspective, Shi-Jiang Lu and Qiang Feng assess the impact of new methods for producing chimeric antigen receptor (CAR) T cell “off-the-shelf” therapeutics. Natural killer (NK) cells are specialized immune effector cells that recognize and kill target cells without human leukocyte antigen restriction or prior sensitization, Received: 21 July 2021 Accepted: 28 July 2021
Medicine